A Randomized Phase 2 Study of Losartan and Nivolumab in Combination with FOLFIRINOX and SBRT in Localized Pancreatic Cancer (Stand up to Cancer)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Pancreatic Cancer
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    Histologically confirmed localized pancreatic adenocarcinoma; borderline/potentially resectable or locally advanced. Baseline Systolic Blood Pressure (SBP) > 100 mm Hg. Normal organ and marrow function as defined below: absolute neutrophil count > 1,500 mm3, platelets > 100,000/mm3, total bilirubin 1.5 x institutional upper limit of normal if no biliary stenting has been done OR 2.0 x upper limit of normal if patient is s/p biliary stenting OR two down trending values, and etc.

You may not be eligible for this study if the following are true:

  • Patients enrolled to the randomized portion of the study (arms 1 thru 3) may not be already treated on ACE or ARB therapy for hypertension or renal protection (with diabetes) at the time of enrollment. If patients are receiving ACE or ARB therapy, they may ONLY be considered for the exploratory arm, Arm 4. Serious concomitant systemic disorders incompatible with the study (at the discretion of the investigator). Any prior chemotherapy, radiation therapy, immunotherapy, or biologic ( targeted ) therapy for treatment of the patient's pancreatic tumor.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.